You are here

Home » Content

PROGRAMLI HEMODİYALİZ HASTALARINDA REKOMBİNANT İNSAN ERİTROPOİETİNİNİN TAM KAN VİSKOZİTESİNE ETKİSİ VE HİPERTANSİYONLA İLİŞKİSİ

THE EFFECT OF RECOMBINANT HUMAN ERYTHROPOIETIN AN WHOLE BLOOD VISCOSITY AND IT'S RELATION WITH HYPERTENSION IN THE PATIENTS ON REGULAR HEMODIALYSIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1998

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The effect of recombinant human erythropoietin (r-HuEpo) on whole blood viscosity regarding its relation with hypertension was investigated in this study. 15 patients with mean hemoglobin level of less than 9 gr/dl and without any reason other than uremia for the present anemia were included in the study group. The control group included 10 healthy volunteer with mean hemoglobin level of 12.7 gr/dl. We started r-HuEpo therapy with an initial dose of 50 U/kg three times weekly and increased the dose in order to reach the target hemoglobin level of 10-12 gr/dl. We observed hemoglobin, hemetocrit, whole blood viscosity , and blood pressure changes before and after the therapy. Although the increase in whole blood viscosity was statistically significant (p<0.05) the increase in blood pressure levels were not. According to this result whole blood viscosity was not the only factor playing role in the acceleration or development of hypertension.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada programlı hemodiyaliz uygulanan kronik böbrek yetmezliği hastalarında rekombinant insan eritopoietin (r-HuEpo) tedavisinin tam kan viskozitesine etkisi ve hipertansiyonla ilişkisi araştınldı.Çalışma grubunu ortalama hemoglobin düzeyleri 9 gr/dl altında olan, mevcut anemisi için üremi dışında bir neden tespit edilemeyen 15 hasta oluşturdu.Kontrol grubuna ortalama hemoglobin düzeyleri 12.7 gr/dl olan 10 normal sağlıklı gönüllü dahil edildi.Çalışma grubundaki hastalara haftada 3 kez 50 U/kg 'dan başlanarak hedef hemoglobin düzeyi 10-12 gr/dl olacak şekilde r-HuEpo tedavisi uygulandı. Tedavi öncesi ve sonrasında hemoglobin, hematokrit, tam kan viskozitesi ve kan basınçları izlendi.Tam kan viskozitesinde istatistiksel olarak anlamlı bir artış (p<0.05) gözlenmesine rağmen kan basınçlarında izlenen artış istatistiksel olarak anlamlı bulunmamıştır. Buna göre mevcut hipertansiyonun şiddetlenmesinde veya yeni hipertansiyon gelişmesinde tam kan viskozitesinin tek başına rol oynamadığı sonucuna varılmıştır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_209.pdf
  • 2
79-82
  • Turkish

REFERENCES

References: 

1. McDougall 1C, Davies ME, Hutton RD, et al.
Rheological studies during treatment of renal anemia with recombinant human eythropoietin. Br Med J 1991;77:550-558.
2. Canaud B, Donadieu P, Polito C, et al. Erythropoietin-associated hypertension: what role for blood viscosity changes? Nephron 1989; 51:430-431.
3. Bönler T, Leo A, Linderkamp O, et al. Haemorheological changes in uremic children in response to erythropoietin treatment. Nephrol Dial
Transplant 1993;8: 140-145
4. Fahey JL, Barth WF, Solomon A. Serum hyperviscosity
syndrome. JAMA 1965; 192, 6: 120-3.
5. Reinke W , Gaethengs P, Johnson PC. Blood viscosity in small tubes: effect of shear rate , aggregation and sedimantation. Am J Physiol 1987; 253(3 Pt 2):540-7.
6. Escbach JW, Adamson JW. Hematologic consequences of renal failure. In: Brenner and Rector's (eds). The
Kidney 4th ed. Saunder's Company. 1991; 2019-2035.
7. Escbach JW, Egrie JC, Downing MR, etal. Correction of anemia of end stage renal disease with recombinant
human erythropoietin. N Engl J Med 1987; 316; 2: 73¬8.
8. Dreyling KW, Steinhaver HB, Geiger H, et al. Platelet
function under recombinant human erythropoietin
81
therapy in haemodialysis patients. Nephrol Dial 12. Transplant 1989; 4: 472.
9. Geet C, Huglustaine D, Verresan L, et al. Haemostatic effects of recombinant human eythropoietin in chronic ^ haemodialysis patients. Thrombosis and Haemostasis
1989; 61(1): 117-121.
10. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications 14. of erythropoietin therapy. Lancet i :1988; 97-100.
11. Brown DC, Kieran M, Thomas LL, et al. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit. Nephron 1991; 59: 394-98.
Gansevoort RT, Vaziri ND, De Jang PE. Treatment of anemia of nephrotic syndrome with recombinant
erythropoietin. Am J Kidney Dis 1996; 28: 2, 274-7.
Shand BI, Buttimore AL, Lynn KL, et al. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity. Ren Fail 1994; 16(3): 407-13.
Haedersdal C, Mehlsen J, Stenver D, et al. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
Angiology 1994; 45(3): 231-4.
82

Thank you for copying data from http://www.arastirmax.com